Page 144 - Read Online

Sorrentino et al. Role of A 2B receptor in cancer

31. Ferrari D, Malavasi F, Antonioli L. A purinergic trail for metastases. 49. Leclerc BG, Charlebois R, Chouinard G, Allard B, Pommey S, Saad
Trends Pharmacol Sci 2017;38:277-90. F, Stagg J. CD73 expression is an independent prognostic factor in
32. St. Hilaire C, Carroll SH, Chen H, Ravid K. Mechanisms of induction prostate cancer. Clin Cancer Res 2016;22:158-66.
of adenosine receptor genes and its functional significance. J Cell 50. Turcotte M, Spring K, Pommey S, Chouinard G, Cousineau I, George
Physiol 2009;218:35-44. J, Chen GM, Gendoo DM, Haibe-Kains B, Karn T, Rahimi K, Le
33. Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases Page C, Provencher D, Mes-Masson AM, Stagg J. CD73 is associated
CD39 and CD73: Novel checkpoint inhibitor targets. Immunol Rev with poor prognosis in high-grade serous ovarian cancer. Cancer Res
2017;276:121-44. 2015;75:4494-503.
34. Raskovalova T, Lokshin A, Huang X, Su Y, Mandic M, Zarour 51. Serra S, Horenstein AL, Vaisitti T, Brusa D, Rossi D, Laurenti L,
HM, Jackson EK, Gorelik E. Inhibition of cytokine production D’Arena G, Coscia M, Tripodo C, Inghirami G, Robson SC, Gaidano
and cytotoxic activity of human antimelanoma specific CD8+ and G, Malavasi F, Deaglio S. CD73-generated extracellular adenosine in
CD4+ T lymphocytes by adenosine-protein kinase A type I signaling. chronic lymphocytic leukemia creates local conditions counteracting
Cancer Res 2007;67:5949-56. drug-induced cell death. Blood 2011;118:6141-52.
35. Zarek PE, Huang CT, Lutz ER, Kowalski J, Horton MR, Linden J, 52. Wennerberg E, Kawashima N, Demaria S. Adenosine regulates
Drake CG, Powell JD. A2A receptor signaling promotes peripheral radiation therapy-induced anti-tumor immunity. J ImmunoTher
tolerance by inducing T-cell anergy and the generation of adaptive Cancer 2015;3:378.
regulatory T cells. Blood 2008;111:251-9. 53. Allard B, Pommey S, Smyth MJ, Stagg J. Targeting CD73 enhances
36. Lappas CM, Rieger JM, Linden J. A2A adenosine receptor induction the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin
inhibits IFN-gamma production in murine CD4+ T cells. J Immunol Cancer Res 2013;19:5626-35.
2005;174:1073-80. 54. Beavis PA, Divisekera U, Paget C, Chow MT, John LB, Devaud C,
37. Sevigny CP, Li L, Awad AS, Huang L, McDuffie M, Linden J, Dwyer K, Stagg J, Smyth MJ, Darcy PK. Blockade of A2A receptors
Lobo PI, Okusa MD. Activation of adenosine A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad
attenuates allograft rejection and alloantigen recognition. J Immunol Sci U S A 2013;110:14711-6.
2007;178:4240-9. 55. Iannone R, Miele L, Maiolino P, Pinto A, Morello S. Adenosine
38. Panther E, Corinti S, Idzko M, Herouy Y, Napp M, la Sala A, limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse
Girolomoni G, Norgauer J. Adenosine affects expression of membrane melanoma model. Am J Cancer Res 2014;4:172-81.
molecules, cytokine and chemokine release, and the T-cell stimulatory 56. Mittal D, Young A, Stannard K, Yong M, Teng MW, Allard B, Stagg J,
capacity of human dendritic cells. Blood 2003;101:3985-90. Smyth MJ. Antimetastatic effects of blocking PD-1 and the adenosine
39. Cekic C, Day YJ, Sag D, Linden J. Myeloid expression of adenosine A2A receptor. Cancer Res 2014;74:3652-8.
A2A receptor suppresses T and NK cell responses in the solid tumor 57. Mittal D, Sinha D, Barkauskas D, Young A, Kalimutho M, Stannard
microenvironment. Cancer Res 2014;74:7250-9. K, Caramia F, Haibe-Kains B, Stagg J, Khanna KK, Loi S, Smyth
40. Morello S, Pinto A, Blandizzi C, Antonioli L. Myeloid cells in the MJ. Adenosine 2B receptor expression on cancer cells promotes
tumor microenvironment: role of adenosine. Oncoimmunology metastasis. Cancer Res 2016;76:4372-82.
2015;5:e1108515. 58. Bastid J, Cottalorda-Regairaz A, Alberici G, Bonnefoy N, Eliaou JF,
41. Ohta A, Sitkovsky M. Extracellular adenosine-mediated modulation Bensussan A. ENTPD1/CD39 is a promising therapeutic target in
of regulatory T cells. Front Immunol 2014;5:304. oncology. Oncogene 2013;32:1743-51.
42. Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, 59. Fishman P, Bar-Yehuda S, Ohana G, Barer F, Ochaion A, Erlanger
Denoyer D, Dwyer KM, Smyth MJ. Anti-CD73 antibody therapy A, Madi L. An agonist to the A3 adenosine receptor inhibits colon
inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A carcinoma growth in mice via modulation of GSK-3 beta and NF-
2010;107:1547-52. kappa B. Oncogene 2004;23:2465-71.
43. Jin D, Fan J, Wang L, Thompson LF, Liu A, Daniel BJ, Shin T, Curiel 60. Cohen S, Stemmer SM, Zozulya G, Ochaion A, Patoka R, Barer F,
TJ, Zhang B. CD73 on tumor cells impairs antitumor T-cell responses: Bar-Yehuda S, Rath-Wolfson L, Jacobson KA, Fishman P. CF102
a novel mechanism of tumor-induced immune suppression. Cancer an A3 adenosine receptor agonist mediates anti-tumor and anti-
Res 2010;70:2245-55. inflammatory effects in the liver. J Cell Physiol 2011;226:2438-47.
44. Wang L, Fan J, Thompson LF, Zhang Y, Shin T, Curiel TJ, Zhang B. 61. Jajoo S, Mukherjea D, Watabe K, Ramkumar V. Adenosine A(3)
CD73 has distinct roles in non-hematopoietic and hematopoietic cells receptor suppresses prostate cancer metastasis by inhibiting NADPH
to promote tumor growth in mice. J Clin Invest 2011;121:2371-82. oxidase activity. Neoplasia 2009;11:1132-45.
45. Forte G, Sorrentino R, Montinaro A, Luciano A, Adcock IM, Maiolino 62. Morello S, Sorrentino R, Montinaro A, Luciano A, Maiolino P, Ngkelo
P, Arra C, Cicala C, Pinto A, Morello S. Inhibition of CD73 improves A, Arra C, Adcock IM, Pinto A. NK1.1 cells and CD8 T cells mediate
B cell-mediated anti-tumor immunity in a mouse model of melanoma. the antitumor activity of Cl-IB-MECA in a mouse melanoma model.
J Immunol 2012;189:2226-33. Neoplasia 2011;13:365-73.
46. Loi S, Pommey S, Haibe-Kains B, Beavis PA, Darcy PK, Smyth 63. Montinaro A, Forte G, Sorrentino R, Luciano A, Palma G, Arra C,
MJ, Stagg J. CD73 promotes anthracycline resistance and poor Adcock IM, Pinto A, Morello S. Adoptive immunotherapy with Cl-
prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A IB-MECA-treated CD8+ T cells reduces melanoma growth in mice.
2013;110:11091-6. PLoS One 2012;7:e45401.
47. Yegutkin GG, Marttila-Ichihara F, Karikoski M, Niemelä J, Laurila 64. Silverman MH, Strand V, Markovits D, Nahir M, Reitblat T, Molad
JP, Elima K, Jalkanen S, Salmi M. Altered purinergic signaling in Y, Rosner I, Rozenbaum M, Mader R, Adawi M, Caspi D, Tishler
CD73-deficient mice inhibits tumor progression. Eur J Immunol M, Langevitz P, Rubinow A, Friedman J, Green L, Tanay A, Ochaion
2011;41:1231-41. A, Cohen S, Kerns WD, Cohn I, Fishman-Furman S, Farbstein M,
48. Quezada C, Garrido W, Oyarzún C, Fernández K, Segura R, Melo R, Yehuda SB, Fishman P. Clinical evidence for utilization of the A3
Casanello P, Sobrevia L, San Martín R. 5’-ectonucleotidase mediates adenosine receptor as a target to treat rheumatoid arthritis: data from a
multiple-drug resistance in glioblastoma multiforme cells. J Cell phase II clinical trial. J Rheumatol 2008;35:41-8.
Physiol 2013;228:602-8. 65. Fishman P, Bar-Yehuda S, Liang BT, Jacobson KA. Pharmacological
136 Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ July 17, 2017